Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)

AstraZeneca

Status: Enrolling

Conditions: Metastatic Castration-resistant Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT06380738

D0817R00074 (Other Identifier)

Details and patient eligibility

About

PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCRPC setting. Clinical outcomes will be assessed in patients who are either NHA-naive or NHA-exposed prior to initiating olaparib + abiraterone treatment, respectively. Patient demographic and clinical characteristics, as well as treatment received prior and subsequent to olaparib + abiraterone, will also be described. The study plans to enroll patients for a maximum of 2 years and follow up patients from initiation of olaparib until 1 year post last patient in.

Enrollment: 250 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Willing and able to provide written informed consent;
• 18 years of age and above;
• Documented histopathology or cytopathology of PCa, adenocarcinoma;
• Confirmed as mCRPC;
• Initiated olaparib + abiraterone after site activation

Exclusion criteria

• Patients participating in a clinical trial with an investigational prostate cancer treatment within 30 days prior to olaparib initiation